Universal STAR-T cells for autoimmune diseases with low platelets of unknown cause
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This early-phase trial is testing a new cell therapy for people with certain autoimmune diseases where the immune system attacks blood platelets, causing bleeding problems. The treatment is designed to stop this attack and could be an option if standard medications haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have a connective tissue disease, such as lupus, Sjögren's syndrome, or a related condition
- You have low blood platelet counts (below 30, or below 50 with bleeding symptoms) that are definitely caused by your immune system
- You have already tried at least one strong steroid treatment or combination with other immune-suppressing drugs for at least 3 months and it didn't work well enough
- Your major organs (like liver, kidneys, and bone marrow) are working well enough, and you do not have serious infections or recent cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding another medicine (telitacicept) to a standard platelet-boosting drug (eltrombopag) works better than eltrombopag alone for adults with ITP that hasn't improved with steroids. The goal is to help raise your platelet counts and reduce bleeding risk.
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
This early-phase trial tests an investigational cell therapy called PRG-1801 for people with immune thrombocytopenia (ITP) that hasn't responded to or has come back after standard treatments. It aims to see if PRG-1801 can safely help raise platelet counts.
This study looks at blood test antibodies to help confirm whether low platelet counts are caused by an autoimmune condition. It may help doctors better classify your type of low platelets and guide appropriate next steps.
This trial tests a new CAR-T cell treatment called Inaticabtagene Autoleucel for people with lupus that causes very low platelet counts (immune thrombocytopenia) that hasn't gotten better with standard treatments. The goal is to see if it can help raise platelet levels.
This trial tests a combination of two medicines (atorvastatin and N-acetylcysteine) added to romiplostim for adults with immune thrombocytopenia (ITP) that hasn't responded well to steroids. The goal is to help raise your platelet count and reduce bleeding risk.
Hear when a new Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.